Rémy Cointreau (RMC) Q3 24/25 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q3 24/25 TU earnings summary
9 Jan, 2026Executive summary
Q3 2024-25 organic sales declined 21.5% year-over-year, with 9M sales down 17.8% due to high comparables, US destocking, and challenging conditions in China and APAC travel retail, partially offset by growth in Europe and direct channels in Asia.
Americas experienced a sharp Q3 sales drop, APAC saw declines mainly from China, while EMEA showed sequential improvement driven by Liqueurs & Spirits.
Direct-to-consumer and e-commerce channels in China showed resilience and double-digit growth, especially during Double 11 and Super Brand Day.
Cost-cutting measures are being executed as planned, with a plan exceeding €50 million.
Financial highlights
9M 2024-25 group sales were €787.8 million, down 17.7% reported and 17.8% organic; Q3 sales were €254.1 million, down 20.6% reported and 21.5% organic year-over-year.
Volume effects contributed -13.8% and price/mix -7.7% to Q3 sales decline; currency impact was minimal at €1.3 million for 9M.
Cognac 9M organic sales fell 19.0% (volume -14.7%, price-mix -4.3%); Liqueurs & Spirits dropped 14.9% (volume -12.2%, price-mix -2.7%).
Partner Brands sales declined 26.5% organically to €16.3 million.
Outlook and guidance
Full-year 2024-25 organic sales decline expected near -18%, at the lower end of the -15% to -18% range.
Current operating margin (COP) forecasted between 21% and 22% organically.
FX expected to have a positive impact of €2–5 million on sales and €5–10 million on operating profit.
No Americas growth expected before Q4 2024-25; APAC to see further sequential deterioration; EMEA to remain subdued.
2029–2030 midterm guidance reconfirmed, with targets of 72% gross margin and 33% COP margin.
Latest events from Rémy Cointreau
- Q3 organic sales up 2.8% as U.S. and EMEA gains offset APAC and China weakness.RMC
Q3 2026 TU3 Feb 2026 - Q1 sales dropped 15.6% organically, with gradual recovery and cost controls underway.RMC
Q1 24/25 TU3 Feb 2026 - Sales and profit dropped, but cost savings and recovery with high single-digit growth are targeted.RMC
H2 23/241 Feb 2026 - H1 sales dropped 15.9% organically, triggering revised guidance and a major cost-cutting plan.RMC
H1 24/25 TU18 Jan 2026 - Sales and profit dropped, but margins held up due to aggressive cost controls.RMC
H1 24/2512 Jan 2026 - Sales fell 18% organically; margin guidance held, cost savings and tariff risks remain.RMC
Q4 24/25 TU29 Nov 2025 - Sales and profit declined, but transformation and investment in recovery continue.RMC
H1 25/2627 Nov 2025 - Sales and profit fell sharply, but cost savings and a US rebound support cautious optimism.RMC
H2 24/2521 Nov 2025 - H1 sales dropped 4.2% organically, prompting a guidance cut amid China and currency headwinds.RMC
Q2 25/26 TU31 Oct 2025